# A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

> **NCT03598621** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 68 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide, 0.5 mg/mL
- **DRUG:** Semaglutide, 1.0 mg/mL
- **DRUG:** Semaglutide, 1.34 mg/mL
- **DRUG:** Semaglutide, 2.0 mg/mL
- **DEVICE:** DV3372, 0.5 mg/mL
- **DEVICE:** DV3372, 1.0 mg/mL
- **DEVICE:** PDS290
- **DEVICE:** NovoPen®4

## Key facts

- **NCT ID:** NCT03598621
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-23
- **Primary completion:** 2019-01-17
- **Final completion:** 2019-01-17
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598621, "A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03598621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*